TACROLIMUS EXTENDED-RELEASE CAPSULES

TACROLIMUS EXTENDED-RELEASE CAPSULES was reported 127607 times

TACROLIMUS EXTENDED-RELEASE CAPSULES is most commonly taken among patients reporting these side effects:

# Side effect Count Frequency
0 CALCINEURIN INHIBITOR INDUCED PAIN SYNDROME 86 0.9348
1 NEW ONSET DIABETES AFTER TRANSPLANTATION 155 0.8960
2 MALACOPLAKIA 397 0.8668
3 TRANSPLANTATION ASSOCIATED FOOD ALLERGY 85 0.8416
4 SMOOTH MUSCLE CELL NEOPLASM 334 0.7990
5 TRICHODYSPLASIA SPINULOSA 303 0.7953
6 RENAL GRAFT INFECTION 183 0.7888
7 PHAEOHYPHOMYCOSIS 372 0.7766
8 POST TRANSPLANT DISTAL LIMB SYNDROME 152 0.7488
9 POLYOMAVIRUS-ASSOCIATED NEPHROPATHY 1736 0.7403
10 DELAYED GRAFT FUNCTION 486 0.6835
11 POLYOMAVIRUS VIRAEMIA 716 0.6742
12 RHODOCOCCUS INFECTION 106 0.6386
13 ALTERNARIA INFECTION 234 0.6290
14 CHRONIC ALLOGRAFT NEPHROPATHY 465 0.5939
15 PARVOVIRUS B19 INFECTION 530 0.5922
16 POST TRANSPLANT LYMPHOPROLIFERATIVE DISORDER 2975 0.5839
17 DONOR SPECIFIC ANTIBODY PRESENT 89 0.5779
18 HUMAN POLYOMAVIRUS INFECTION 303 0.5706
19 IMMUNOSUPPRESSANT DRUG LEVEL INCREASED 1875 0.5672
20 PANCREAS TRANSPLANT REJECTION 111 0.5522
21 RENAL TRANSPLANT FAILURE 543 0.5496
22 HUMAN HERPESVIRUS 8 INFECTION 324 0.5320
23 TRANSPLANT REJECTION 4151 0.5176
24 PULMONARY NOCARDIOSIS 424 0.5146
25 TRANSPLANT DYSFUNCTION 919 0.5146
26 CEREBRAL NOCARDIOSIS 119 0.5107
27 COMPLICATIONS OF TRANSPLANTED KIDNEY 1129 0.4974
28 CYTOMEGALOVIRUS SYNDROME 82 0.4970
29 EPIDERMODYSPLASIA VERRUCIFORMIS 82 0.4881
30 HEART TRANSPLANT REJECTION 499 0.4807
31 ACANTHAMOEBA INFECTION 90 0.4787
32 DISSEMINATED BLASTOMYCOSIS 79 0.4620
33 PULMONARY MUCORMYCOSIS 243 0.4602
34 GASTROINTESTINAL MUCORMYCOSIS 76 0.4551
35 HUMAN EHRLICHIOSIS 95 0.4545
36 DISSEMINATED MUCORMYCOSIS 178 0.4518
37 IMMUNOSUPPRESSANT DRUG LEVEL DECREASED 540 0.4500
38 COMPLICATIONS OF TRANSPLANTED LUNG 135 0.4397
39 EPSTEIN-BARR VIRAEMIA 486 0.4382
40 BLASTOMYCOSIS 208 0.4280
41 LIVER TRANSPLANT REJECTION 769 0.4277
42 BK VIRUS INFECTION 1419 0.4203
43 GRAFT LOSS 304 0.4193
44 CHRONIC GRAFT VERSUS HOST DISEASE IN EYE 85 0.4187
45 CHRONIC GRAFT VERSUS HOST DISEASE ORAL 102 0.4163
46 CRYPTOSPORIDIOSIS INFECTION 217 0.4133
47 MONKEYPOX 114 0.4130
48 TRUNCUS ARTERIOSUS PERSISTENT 77 0.3869
49 CYTOMEGALOVIRUS VIRAEMIA 1718 0.3858
50 SCEDOSPORIUM INFECTION 272 0.3853
51 LUNG TRANSPLANT REJECTION 249 0.3773
52 MICROSPORIDIA INFECTION 132 0.3761
53 NOCARDIOSIS 954 0.3727
54 CHRONIC GRAFT VERSUS HOST DISEASE IN SKIN 343 0.3704
55 TRICHOPHYTOSIS 78 0.3679
56 KIDNEY TRANSPLANT REJECTION 1760 0.3664
57 DERMATOPHYTOSIS 100 0.3521
58 CYTOMEGALOVIRUS GASTRITIS 88 0.3478
59 MYCOBACTERIUM HAEMOPHILUM INFECTION 99 0.3462
60 ADENOVIRAL HEPATITIS 78 0.3319
61 HUMAN HERPESVIRUS 6 ENCEPHALITIS 93 0.3275
62 CHRONIC GRAFT VERSUS HOST DISEASE IN LIVER 116 0.3187
63 UREAPLASMA INFECTION 130 0.3186
64 CYTOMEGALOVIRUS GASTROINTESTINAL INFECTION 94 0.3154
65 WEST NILE VIRAL INFECTION 236 0.3147
66 VIRAL HAEMORRHAGIC CYSTITIS 223 0.3132
67 RENAL TUBULAR ATROPHY 276 0.3129
68 CYTOMEGALOVIRUS ENTERITIS 111 0.3118
69 GRAFT VERSUS HOST DISEASE IN LUNG 149 0.3117
70 CYSTITIS VIRAL 119 0.3107
71 ADENOVIRUS INFECTION 896 0.3086
72 CAT SCRATCH DISEASE 124 0.3085
73 GRAFT VERSUS HOST DISEASE IN SKIN 678 0.3075
74 TRANSPLANT FAILURE 748 0.3048
75 GRAFT VERSUS HOST DISEASE IN GASTROINTESTINAL TRACT 648 0.3042
76 DISSEMINATED CRYPTOCOCCOSIS 230 0.3038
77 MUCORMYCOSIS 779 0.2995
78 IDIOPATHIC PNEUMONIA SYNDROME 89 0.2987
79 INFECTION REACTIVATION 341 0.2978
80 ACUTE GRAFT VERSUS HOST DISEASE IN SKIN 821 0.2967
81 EPSTEIN-BARR VIRUS INFECTION REACTIVATION 382 0.2901
82 CRYPTOCOCCOSIS 466 0.2857
83 ALVEOLAR PROTEINOSIS 167 0.2821
84 RENAL TUBULAR INJURY 342 0.2815
85 HEPATIC ARTERY THROMBOSIS 82 0.2799
86 CYTOMEGALOVIRUS INFECTION REACTIVATION 1217 0.2752
87 ACUTE GRAFT VERSUS HOST DISEASE IN INTESTINE 386 0.2732
88 ENTEROCOLITIS VIRAL 82 0.2697
89 ACUTE GRAFT VERSUS HOST DISEASE IN LIVER 193 0.2684
90 CHRONIC GRAFT VERSUS HOST DISEASE 970 0.2684
91 FOCAL SEGMENTAL GLOMERULOSCLEROSIS 428 0.2670
92 CYTOMEGALOVIRUS OESOPHAGITIS 98 0.2663
93 HEPATITIS E 416 0.2633
94 FUNGAL ENDOCARDITIS 77 0.2558
95 THROMBOTIC MICROANGIOPATHY 2495 0.2558
96 KIDNEY FIBROSIS 444 0.2558
97 LYMPHOCELE 167 0.2515
98 SYSTEMIC MYCOSIS 288 0.2466
99 CYTOMEGALOVIRUS INFECTION 4081 0.2453
100 EPSTEIN-BARR VIRUS INFECTION 1534 0.2453
101 EPSTEIN-BARR VIRUS ASSOCIATED LYMPHOPROLIFERATIVE DISORDER 433 0.2448
102 GRAFT VERSUS HOST DISEASE IN LIVER 174 0.2430
103 ACUTE GRAFT VERSUS HOST DISEASE 1108 0.2418
104 ATYPICAL HAEMOLYTIC URAEMIC SYNDROME 196 0.2411
105 HISTOPLASMOSIS DISSEMINATED 379 0.2387
106 STRONGYLOIDIASIS 377 0.2331
107 JC VIRUS INFECTION 366 0.2288
108 VIRAEMIA 315 0.2273
109 MENINGITIS CRYPTOCOCCAL 396 0.2263
110 STENOTROPHOMONAS INFECTION 305 0.2248
111 CYTOMEGALOVIRUS COLITIS 516 0.2242
112 ENGRAFTMENT SYNDROME 132 0.2234
113 DISSEMINATED VARICELLA ZOSTER VIRUS INFECTION 81 0.2231
114 TOXOPLASMOSIS 232 0.2148
115 INFECTIVE ANEURYSM 106 0.2141
116 DISSEMINATED ASPERGILLOSIS 101 0.2140
117 PNEUMONIA CYTOMEGALOVIRAL 411 0.2114
118 GRAFT COMPLICATION 124 0.2112
119 CEREBRAL ASPERGILLOSIS 129 0.2098
120 ANGIOSARCOMA 96 0.2082
121 MYCOBACTERIUM ABSCESSUS INFECTION 148 0.2070
122 CHOROIDITIS 77 0.2059
123 ASPERGILLUS INFECTION 1308 0.1991
124 GRAFT VERSUS HOST DISEASE 1427 0.1982
125 PNEUMOCYSTIS JIROVECII INFECTION 235 0.1967
126 CORYNEBACTERIUM INFECTION 105 0.1963
127 PNEUMONIA CRYPTOCOCCAL 185 0.1958
128 LOCKED-IN SYNDROME 90 0.1952
129 TRICHOSPORON INFECTION 79 0.1951
130 GLOMERULONEPHRITIS MEMBRANOPROLIFERATIVE 102 0.1947
131 VARICELLA ZOSTER VIRUS INFECTION 395 0.1904
132 BRAIN ABSCESS 478 0.1887
133 HUMAN HERPESVIRUS 6 INFECTION 357 0.1887
134 KLEBSIELLA INFECTION 944 0.1865
135 ENTEROCOCCAL INFECTION 894 0.1848
136 CEREBRAL TOXOPLASMOSIS 170 0.1820
137 KLEBSIELLA BACTERAEMIA 170 0.1789
138 NECROTISING OESOPHAGITIS 89 0.1784
139 MYCOPLASMA INFECTION 135 0.1729
140 MICROANGIOPATHIC HAEMOLYTIC ANAEMIA 136 0.1726
141 CYTOMEGALOVIRUS TEST POSITIVE 307 0.1721
142 FUSARIUM INFECTION 120 0.1714
143 OSMOTIC DEMYELINATION SYNDROME 126 0.1707
144 GLOMERULOSCLEROSIS 107 0.1693
145 EPSTEIN-BARR VIRUS ASSOCIATED LYMPHOMA 100 0.1692
146 BRONCHOPULMONARY ASPERGILLOSIS 1256 0.1618
147 ACINETOBACTER INFECTION 177 0.1616
148 VISCERAL LEISHMANIASIS 116 0.1607
149 EPSTEIN-BARR VIRUS TEST POSITIVE 99 0.1569
150 URETERIC STENOSIS 121 0.1511
151 ENTEROVIRUS INFECTION 127 0.1470
152 ENTEROBACTER INFECTION 244 0.1451
153 MEDIASTINITIS 84 0.1448
154 GASTROENTERITIS NOROVIRUS 192 0.1445
155 SECONDARY IMMUNODEFICIENCY 173 0.1424
156 INFECTION IN AN IMMUNOCOMPROMISED HOST 101 0.1407
157 ENCEPHALITIS VIRAL 168 0.1379
158 HISTOPLASMOSIS 244 0.1377
159 PNEUMONIA PSEUDOMONAL 210 0.1368
160 MYCOBACTERIAL INFECTION 235 0.1363
161 POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME 1285 0.1345
162 NOROVIRUS INFECTION 192 0.1330
163 PNEUMATOSIS INTESTINALIS 370 0.1296
164 PROTEUS INFECTION 93 0.1295
165 DRUG LEVEL FLUCTUATING 115 0.1295
166 OBLITERATIVE BRONCHIOLITIS 170 0.1295
167 ENTEROCOCCAL SEPSIS 104 0.1284
168 NODULAR REGENERATIVE HYPERPLASIA 81 0.1262
169 MYCOBACTERIUM CHELONAE INFECTION 92 0.1245
170 ENTEROCOCCAL BACTERAEMIA 131 0.1236
171 HAEMOLYTIC URAEMIC SYNDROME 284 0.1224
172 NECROTISING RETINITIS 77 0.1203
173 PNEUMOCYSTIS JIROVECII PNEUMONIA 1188 0.1182
174 PNEUMONIA KLEBSIELLA 217 0.1179
175 RENAL VEIN THROMBOSIS 79 0.1169
176 VENOOCCLUSIVE LIVER DISEASE 577 0.1167
177 CYSTITIS HAEMORRHAGIC 469 0.1162
178 NEPHROPATHY TOXIC 1288 0.1146
179 APLASIA PURE RED CELL 394 0.1144
180 PSEUDOMONAS INFECTION 972 0.1132
181 ACTINIC KERATOSIS 294 0.1132
182 HERPES ZOSTER DISSEMINATED 90 0.1121
183 CYTOMEGALOVIRUS CHORIORETINITIS 215 0.1101
184 SUPERINFECTION BACTERIAL 87 0.1097
185 IGA NEPHROPATHY 182 0.1096
186 ESCHERICHIA INFECTION 888 0.1078
187 CYTOMEGALOVIRUS ENTEROCOLITIS 83 0.1078
188 ANOGENITAL WARTS 96 0.1076
189 HAEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS 790 0.1052
190 SINUSITIS FUNGAL 83 0.1035
191 CENTRAL NERVOUS SYSTEM INFECTION 116 0.1012
192 SYSTEMIC CANDIDA 254 0.1011
193 VACCINATION FAILURE 167 0.1004
194 HYPERTROPHIC CARDIOMYOPATHY 155 0.1001
195 PSEUDOMONAL BACTERAEMIA 85 0.0995
196 RENAL ARTERY STENOSIS 137 0.0993
197 INFECTIOUS PLEURAL EFFUSION 151 0.0991
198 GINGIVAL HYPERTROPHY 150 0.0988
199 PAPILLOMA VIRAL INFECTION 163 0.0987
200 GLOMERULONEPHRITIS MEMBRANOUS 116 0.0986
201 DIFFUSE LARGE B-CELL LYMPHOMA 756 0.0980
202 ACUTE MYELOID LEUKAEMIA RECURRENT 210 0.0977
203 TRANSITIONAL CELL CARCINOMA 126 0.0971
204 ILEAL ULCER 97 0.0958
205 GLOMERULONEPHRITIS 232 0.0947
206 ESCHERICHIA BACTERAEMIA 222 0.0943
207 CHRONIC HEPATITIS 76 0.0938
208 URINARY TRACT INFECTION ENTEROCOCCAL 87 0.0931
209 NEUROENDOCRINE CARCINOMA OF THE SKIN 91 0.0930
210 DRUG LEVEL INCREASED 1528 0.0922
211 PNEUMONIA FUNGAL 363 0.0919
212 ATYPICAL MYCOBACTERIAL INFECTION 130 0.0919
213 BILE DUCT STENOSIS 110 0.0917
214 SQUAMOUS CELL CARCINOMA OF SKIN 552 0.0913
215 PNEUMOMEDIASTINUM 162 0.0896
216 KLEBSIELLA SEPSIS 100 0.0887
217 STEROID DIABETES 133 0.0886
218 RENAL TUBULAR ACIDOSIS 193 0.0884
219 LYMPHOPROLIFERATIVE DISORDER 253 0.0861
220 CENTRAL NERVOUS SYSTEM LYMPHOMA 118 0.0856
221 VENOOCCLUSIVE DISEASE 214 0.0854
222 LUPUS NEPHRITIS 158 0.0844
223 DISSEMINATED TUBERCULOSIS 216 0.0841
224 PARAINFLUENZAE VIRUS INFECTION 127 0.0834
225 DIFFUSE ALVEOLAR DAMAGE 94 0.0817
226 MULTIPLE ORGAN DYSFUNCTION SYNDROME 2289 0.0807
227 STREPTOCOCCAL BACTERAEMIA 87 0.0800
228 BACTERIAL SEPSIS 256 0.0785
229 HYPOGAMMAGLOBULINAEMIA 516 0.0785
230 PYELONEPHRITIS ACUTE 154 0.0785
231 FUNGAL SKIN INFECTION 308 0.0762
232 PRODUCT INEFFECTIVE FOR UNAPPROVED USE 200 0.0751
233 HERPES SIMPLEX 482 0.0741
234 RENAL TUBULAR NECROSIS 727 0.0740
235 URINARY TRACT INFECTION BACTERIAL 180 0.0711
236 DRUG LEVEL ABOVE THERAPEUTIC 325 0.0709
237 MYCOBACTERIUM AVIUM COMPLEX INFECTION 189 0.0703
238 BACTERAEMIA 832 0.0700
239 NORMOCYTIC ANAEMIA 103 0.0700
240 OPPORTUNISTIC INFECTION 128 0.0692
241 ASPERGILLOSIS 90 0.0689
242 FUNGAEMIA 108 0.0686
243 COCCIDIOIDOMYCOSIS 81 0.0679
244 ESCHERICHIA URINARY TRACT INFECTION 286 0.0672
245 PNEUMONIA INFLUENZAL 78 0.0655
246 IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME 326 0.0654
247 RENAL TRANSPLANT 236 0.0653
248 ENCEPHALITIS AUTOIMMUNE 85 0.0646
249 ORGANISING PNEUMONIA 318 0.0641
250 LUNG CONSOLIDATION 177 0.0632
251 REVERSIBLE CEREBRAL VASOCONSTRICTION SYNDROME 124 0.0628
252 PNEUMOPERITONEUM 116 0.0627
253 AUTOIMMUNE HAEMOLYTIC ANAEMIA 212 0.0618
254 STAPHYLOCOCCAL BACTERAEMIA 267 0.0614
255 SOFT TISSUE INFECTION 112 0.0611
256 LOW BIRTH WEIGHT BABY 484 0.0608
257 PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY 499 0.0604
258 COVID-19 PNEUMONIA 698 0.0591
259 ACUTE RESPIRATORY DISTRESS SYNDROME 1028 0.0581
260 RHINOVIRUS INFECTION 224 0.0575
261 PNEUMONIA PNEUMOCOCCAL 84 0.0567
262 ESCHERICHIA SEPSIS 164 0.0565
263 HAEMATOLOGICAL INFECTION 138 0.0564
264 VASCULAR PSEUDOANEURYSM 97 0.0557
265 PYELONEPHRITIS 473 0.0545
266 MENINGITIS BACTERIAL 78 0.0545
267 LIVER ABSCESS 173 0.0533
268 SEPTIC SHOCK 2296 0.0527
269 OPTIC NEUROPATHY 111 0.0524
270 EMPYEMA 104 0.0523
271 HYPERPARATHYROIDISM SECONDARY 129 0.0514
272 PSEUDOMONAL SEPSIS 90 0.0513
273 PNEUMONIA BACTERIAL 471 0.0513
274 HYDRONEPHROSIS 382 0.0510
275 PATHOGEN RESISTANCE 465 0.0510
276 NEUROTOXICITY 881 0.0502
277 PNEUMONIA STAPHYLOCOCCAL 97 0.0491
278 NEPHROTIC SYNDROME 336 0.0490
279 SQUAMOUS CELL CARCINOMA 458 0.0486
280 HISTIOCYTOSIS HAEMATOPHAGIC 143 0.0481
281 CANDIDA INFECTION 810 0.0479
282 VARICELLA 114 0.0477
283 ENCEPHALITIS 327 0.0472
284 HEPATIC FIBROSIS 162 0.0472
285 ABDOMINAL INFECTION 118 0.0461
286 APLASTIC ANAEMIA 238 0.0455
287 OESOPHAGEAL CANDIDIASIS 180 0.0451
288 PRE-ECLAMPSIA 214 0.0450
289 CLOSTRIDIUM DIFFICILE COLITIS 475 0.0448
290 SCLERODERMA 162 0.0445
291 LUNG ABSCESS 93 0.0443
292 CALCIPHYLAXIS 81 0.0441
293 RENAL TUBULAR DISORDER 124 0.0440
294 LARGE INTESTINAL ULCER 119 0.0438
295 BRAIN HERNIATION 129 0.0431
296 BLOOD CREATININE ABNORMAL 149 0.0430
297 LIVER TRANSPLANT 156 0.0429
298 SHOCK HAEMORRHAGIC 348 0.0427
299 PROTEINURIA 811 0.0426
300 GRANULOMA 147 0.0424
301 PULMONARY ALVEOLAR HAEMORRHAGE 238 0.0424
302 CHOLANGITIS 263 0.0424
303 OESOPHAGEAL STENOSIS 119 0.0418
304 OESOPHAGEAL ULCER 159 0.0413
305 OLIGURIA 253 0.0407
306 HYPERAMMONAEMIA 202 0.0404
307 THROMBOTIC THROMBOCYTOPENIC PURPURA 142 0.0403
308 B-CELL LYMPHOMA 135 0.0397
309 SKIN PAPILLOMA 159 0.0396
310 LYMPHOPENIA 560 0.0396
311 UROSEPSIS 365 0.0395
312 BLOOD IMMUNOGLOBULIN G DECREASED 98 0.0395
313 PREMATURE DELIVERY 619 0.0388
314 STAPHYLOCOCCAL SEPSIS 191 0.0386
315 PNEUMONIA VIRAL 123 0.0385
316 HEPATOSPLENOMEGALY 99 0.0385
317 END STAGE RENAL DISEASE 702 0.0385
318 GUILLAIN-BARRE SYNDROME 186 0.0384
319 ENDOCARDITIS 197 0.0384
320 LEUKOPENIA 1911 0.0382
321 DRUG LEVEL DECREASED 386 0.0379
322 POTENTIATING DRUG INTERACTION 127 0.0378
323 WOUND DEHISCENCE 127 0.0376
324 LUNG OPACITY 99 0.0375
325 ENDOPHTHALMITIS 224 0.0373
326 PULMONARY TUBERCULOSIS 159 0.0372
327 HEPATIC NECROSIS 139 0.0369
328 HYPOALBUMINAEMIA 286 0.0367
329 NOSOCOMIAL INFECTION 81 0.0367
330 TUBULOINTERSTITIAL NEPHRITIS 687 0.0366
331 HEPATITIS C 441 0.0365
332 BACTERIAL INFECTION 680 0.0364
333 ACUTE KIDNEY INJURY 5530 0.0361
334 HYPERURICAEMIA 148 0.0360
335 PORTAL VEIN THROMBOSIS 116 0.0359
336 SUBSTANCE-INDUCED PSYCHOTIC DISORDER 80 0.0357
337 LEFT VENTRICULAR HYPERTROPHY 153 0.0357
338 DENGUE FEVER 82 0.0357
339 DYSLIPIDAEMIA 181 0.0356
340 CUSHINGOID 114 0.0355
341 DRUG INTERACTION 5630 0.0355
342 CLOSTRIDIAL INFECTION 120 0.0354
343 DRUG RESISTANCE 895 0.0348
344 FOETAL GROWTH RESTRICTION 211 0.0347
345 RENAL IMPAIRMENT 2892 0.0344
346 PANCREATITIS NECROTISING 79 0.0343
347 NECROSIS 191 0.0343
348 HEPATITIS B REACTIVATION 108 0.0340
349 STEM CELL TRANSPLANT 85 0.0340
350 RESPIRATORY FAILURE 2472 0.0339
351 BLOOD CREATININE INCREASED 2210 0.0338
352 HEPATOCELLULAR CARCINOMA 255 0.0335
353 PORTAL HYPERTENSION 103 0.0334
354 CYTOPENIA 405 0.0330
355 DERMATOMYOSITIS 83 0.0327
356 ENCEPHALOPATHY 799 0.0325
357 HEPATITIS B 196 0.0325
358 LEUKOENCEPHALOPATHY 120 0.0322
359 RENAL CELL CARCINOMA 156 0.0319
360 ANURIA 270 0.0313
361 DRUG LEVEL BELOW THERAPEUTIC 173 0.0313
362 STAPHYLOCOCCAL INFECTION 1026 0.0311
363 PANCYTOPENIA 1736 0.0310
364 TOXIC ENCEPHALOPATHY 157 0.0310
365 HAEMODYNAMIC INSTABILITY 236 0.0309
366 ENTEROCOLITIS 177 0.0306
367 HYPERVOLAEMIA 150 0.0303
368 ACUTE RESPIRATORY FAILURE 577 0.0300
369 DISSEMINATED INTRAVASCULAR COAGULATION 420 0.0298
370 GASTROINTESTINAL TOXICITY 143 0.0297
371 ENTERITIS 190 0.0297
372 FUNGAL INFECTION 983 0.0295
373 BLOOD CREATINE INCREASED 130 0.0293
374 NEPHROPATHY 274 0.0293
375 LABELLED DRUG-DRUG INTERACTION MEDICATION ERROR 259 0.0293
376 NEPHRITIS 97 0.0290
377 SERUM SICKNESS 80 0.0287
378 DUODENITIS 88 0.0287
379 NORMOCHROMIC NORMOCYTIC ANAEMIA 86 0.0286
380 METABOLIC ENCEPHALOPATHY 85 0.0283
381 HAEMOLYTIC ANAEMIA 253 0.0282
382 CHRONIC MYELOID LEUKAEMIA 130 0.0281
383 NEPHROGENIC ANAEMIA 129 0.0278
384 SKIN NECROSIS 144 0.0277
385 SPLENOMEGALY 325 0.0277
386 RESPIRATORY SYNCYTIAL VIRUS INFECTION 240 0.0275
387 SUBCUTANEOUS ABSCESS 131 0.0273
388 IMMUNOSUPPRESSION 241 0.0273
389 HYPERKALAEMIA 947 0.0270
390 DRUG INEFFECTIVE FOR UNAPPROVED INDICATION 1480 0.0269
391 POSTOPERATIVE WOUND INFECTION 182 0.0269
392 IMMUNE THROMBOCYTOPENIA 123 0.0268
393 SYSTEMIC INFLAMMATORY RESPONSE SYNDROME 102 0.0267
394 THERAPY PARTIAL RESPONDER 415 0.0266
395 LUNG ADENOCARCINOMA 80 0.0266
396 PREMATURE BABY 797 0.0265
397 SEPSIS 2944 0.0264
398 HAEMOTHORAX 76 0.0262
399 AZOTAEMIA 102 0.0255
400 HEART DISEASE CONGENITAL 90 0.0254
401 ARTHRITIS BACTERIAL 104 0.0253
402 PROSTATITIS 77 0.0253
403 PRODUCT USE IN UNAPPROVED INDICATION 6165 0.0248
404 ELECTROLYTE IMBALANCE 289 0.0248
405 HYPERTRIGLYCERIDAEMIA 145 0.0247
406 HEPATITIS CHOLESTATIC 149 0.0247
407 PROTEIN URINE PRESENT 123 0.0246
408 ABDOMINAL ABSCESS 109 0.0246
409 CATATONIA 129 0.0245
410 MYOPATHY 211 0.0244
411 HERPES VIRUS INFECTION 140 0.0243
412 ODYNOPHAGIA 145 0.0243
413 LUNG TRANSPLANT 86 0.0243
414 ASCITES 704 0.0239
415 LARGE INTESTINE PERFORATION 165 0.0237
416 CLOSTRIDIUM DIFFICILE INFECTION 517 0.0237
417 SKIN MASS 158 0.0236
418 HYPOMAGNESAEMIA 329 0.0236
419 BRONCHIECTASIS 158 0.0234
420 PULMONARY MASS 348 0.0233
421 INTRACRANIAL PRESSURE INCREASED 130 0.0233
422 HAEMOLYSIS 180 0.0233
423 SKIN WEEPING 83 0.0232
424 ABSCESS LIMB 99 0.0232
425 URINE OUTPUT DECREASED 203 0.0232
426 MULTI-ORGAN FAILURE 401 0.0232
427 BRAIN OEDEMA 292 0.0231
428 SLEEP DISORDER DUE TO GENERAL MEDICAL CONDITION, INSOMNIA TYPE 150 0.0231
429 ACIDOSIS 176 0.0230
430 FOOD ALLERGY 177 0.0229
431 DISEASE RECURRENCE 1086 0.0228
432 BASAL CELL CARCINOMA 355 0.0227
433 FAILURE TO THRIVE 118 0.0227
434 HYPERCALCAEMIA 280 0.0227
435 VIRAL LOAD INCREASED 87 0.0224
436 PAPULE 156 0.0221
437 TOXICITY TO VARIOUS AGENTS 3720 0.0220
438 PULSELESS ELECTRICAL ACTIVITY 92 0.0220
439 DEVICE RELATED INFECTION 336 0.0218
440 METASTASES TO LYMPH NODES 147 0.0218
441 PYODERMA GANGRENOSUM 78 0.0217
442 GASTROENTERITIS 316 0.0216
443 MUCOSAL INFLAMMATION 561 0.0214
444 COVID-19 3756 0.0214
445 PULMONARY HAEMORRHAGE 166 0.0212
446 LUNG INFILTRATION 184 0.0208
447 ACUTE HEPATIC FAILURE 282 0.0206
448 SKIN INFECTION 231 0.0206
449 HYDROCEPHALUS 112 0.0205
450 MENINGITIS 137 0.0205
451 INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION 210 0.0204
452 CACHEXIA 105 0.0204
453 ATELECTASIS 197 0.0204
454 INFLAMMATORY MARKER INCREASED 101 0.0204
455 VASCULAR DEVICE INFECTION 92 0.0203
456 CORONAVIRUS INFECTION 134 0.0202
457 METABOLIC ACIDOSIS 646 0.0202
458 HYPOVOLAEMIA 118 0.0201
459 BONE MARROW FAILURE 408 0.0201
460 PERICARDIAL EFFUSION 460 0.0199
461 NEUROLOGICAL SYMPTOM 113 0.0197
462 HEPATIC FAILURE 592 0.0196
463 ACUTE MYELOID LEUKAEMIA 303 0.0194
464 STREPTOCOCCAL INFECTION 108 0.0194
465 OVARIAN CYST 194 0.0194
466 DERMATITIS ATOPIC 1023 0.0194
467 CARDIAC TAMPONADE 92 0.0193
468 AUTOIMMUNE HEPATITIS 133 0.0191
469 SUSPECTED OFF LABEL USE 86 0.0190
470 RESPIRATORY DISTRESS 525 0.0190
471 HYPERBILIRUBINAEMIA 197 0.0190
472 HYPOVOLAEMIC SHOCK 91 0.0190
473 METASTASES TO LUNG 218 0.0188
474 COLITIS 707 0.0186
475 NORMAL NEWBORN 101 0.0186
476 PLEURAL EFFUSION 1127 0.0185
477 SKIN LESION 508 0.0185
478 INFLAMMATORY BOWEL DISEASE 181 0.0185
479 WOUND INFECTION 202 0.0184
480 MENTAL STATUS CHANGES 510 0.0183
481 PAPILLOEDEMA 82 0.0181
482 FEBRILE NEUTROPENIA 1187 0.0179
483 SHOCK 408 0.0177
484 ARTERIOSCLEROSIS 166 0.0176
485 ILEUS PARALYTIC 78 0.0175
486 BLOOD UREA INCREASED 292 0.0174
487 THERAPY NON-RESPONDER 782 0.0174
488 NEUTROPENIC SEPSIS 124 0.0173
489 GLOMERULAR FILTRATION RATE DECREASED 213 0.0173
490 SKIN PLAQUE 145 0.0172
491 SUBARACHNOID HAEMORRHAGE 174 0.0171
492 OSTEOMYELITIS 308 0.0170
493 STATUS EPILEPTICUS 192 0.0170
494 GESTATIONAL DIABETES 81 0.0170
495 BLOOD ALBUMIN DECREASED 134 0.0169
496 HAEMODIALYSIS 140 0.0167
497 IRON DEFICIENCY ANAEMIA 153 0.0166
498 OESOPHAGITIS 181 0.0166
499 TRANSAMINASES INCREASED 366 0.0164
500 PERITONITIS 340 0.0164
501 LUNG INFECTION 255 0.0164
502 LEUKOCYTOSIS 296 0.0163
503 MYASTHENIA GRAVIS 132 0.0163
504 CHOLESTASIS 312 0.0162
505 HYPERTRANSAMINASAEMIA 113 0.0162
506 THROMBOCYTOPENIA 1812 0.0162
507 MOUTH ULCERATION 341 0.0162
508 MALNUTRITION 181 0.0162
509 MYOSITIS 145 0.0161
510 SLEEP DISORDER DUE TO A GENERAL MEDICAL CONDITION 274 0.0161
511 HAEMORRHAGE INTRACRANIAL 241 0.0161
512 VENTRICULAR SEPTAL DEFECT 92 0.0161
513 INTESTINAL ISCHAEMIA 88 0.0160
514 PULMONARY TOXICITY 113 0.0160
515 HYPERGLYCAEMIA 582 0.0160
516 RALES 92 0.0158
517 HYPOPHOSPHATAEMIA 117 0.0158
518 NEUTROPENIA 2152 0.0158
519 CARDIAC FAILURE ACUTE 105 0.0157
520 GASTRIC ULCER 298 0.0157
521 RENAL FAILURE 2082 0.0157
522 DIABETIC KETOACIDOSIS 376 0.0156
523 DIARRHOEA HAEMORRHAGIC 146 0.0156
524 REBOUND EFFECT 176 0.0156
525 PNEUMOTHORAX 245 0.0154
526 GENERALISED TONIC-CLONIC SEIZURE 255 0.0154
527 RESPIRATORY TRACT INFECTION 397 0.0152
528 PANCREATITIS ACUTE 342 0.0152
529 OFF LABEL USE 13196 0.0151
530 PHOTOSENSITIVITY REACTION 247 0.0149
531 BLOOD MAGNESIUM DECREASED 129 0.0149
532 HYPOXIA 525 0.0149
533 EXPOSURE DURING PREGNANCY 911 0.0146
534 ANGIOPATHY 82 0.0146
535 BLOOD LACTATE DEHYDROGENASE INCREASED 229 0.0144
536 CHRONIC KIDNEY DISEASE 1091 0.0143
537 RETINAL HAEMORRHAGE 102 0.0143
538 INTERSTITIAL LUNG DISEASE 689 0.0142
539 DIABETES MELLITUS 1084 0.0142
540 INTESTINAL PERFORATION 159 0.0142
541 ORAL CANDIDIASIS 186 0.0141
542 COAGULOPATHY 235 0.0141
543 LYMPHADENOPATHY 499 0.0141
544 INFECTION 2012 0.0139
545 SMALL INTESTINAL OBSTRUCTION 171 0.0139
546 METASTASIS 99 0.0139
547 VIRAL INFECTION 458 0.0137
548 TREATMENT FAILURE 1124 0.0136
549 HEPATOTOXICITY 302 0.0135
550 BLOOD POTASSIUM INCREASED 220 0.0135
551 GLUCOSE TOLERANCE IMPAIRED 80 0.0135
552 TUMOUR LYSIS SYNDROME 119 0.0135
553 GASTROINTESTINAL INFECTION 120 0.0134
554 DUODENAL ULCER 94 0.0133
555 HEPATIC ENCEPHALOPATHY 123 0.0132
556 CARDIOGENIC SHOCK 189 0.0132
557 HYPERLIPIDAEMIA 157 0.0131
558 ABSCESS 207 0.0130
559 ECZEMA 678 0.0129
560 HEMIPARESIS 219 0.0129
561 NEUTROPHIL COUNT INCREASED 130 0.0127
562 PRODUCT ADMINISTERED TO PATIENT OF INAPPROPRIATE AGE 77 0.0126
563 PERITONITIS BACTERIAL 127 0.0126
564 URINARY TRACT INFECTION 2136 0.0125
565 MYELODYSPLASTIC SYNDROME 181 0.0125
566 HEPATIC FUNCTION ABNORMAL 460 0.0123
567 LIVER FUNCTION TEST ABNORMAL 358 0.0123
568 CENTRAL NERVOUS SYSTEM LESION 169 0.0123
569 ANAEMIA 2317 0.0121
570 HAEMATURIA 415 0.0121
571 LYMPHOCYTE COUNT DECREASED 213 0.0120
572 CEREBRAL INFARCTION 294 0.0120
573 POLYURIA 98 0.0120
574 LEFT VENTRICULAR DYSFUNCTION 80 0.0119
575 TACHYPNOEA 162 0.0119
576 ADRENAL INSUFFICIENCY 144 0.0119
577 PNEUMONITIS 321 0.0118
578 HERPES ZOSTER 677 0.0118
579 GENERALISED OEDEMA 144 0.0116
580 MATERNAL EXPOSURE DURING PREGNANCY 1027 0.0115
581 FOETAL EXPOSURE DURING PREGNANCY 934 0.0115
582 RENAL DISORDER 534 0.0114
583 ORAL DISORDER 84 0.0114
584 HAEMATOTOXICITY 108 0.0114
585 MALIGNANT MELANOMA 152 0.0113
586 PNEUMONIA 3651 0.0113
587 PYREXIA 3881 0.0112
588 ORAL HERPES 218 0.0112
589 DIALYSIS 158 0.0111
590 SKIN HAEMORRHAGE 165 0.0111
591 ILEUS 138 0.0111
592 SKIN FISSURES 217 0.0111
593 HEPATOMEGALY 108 0.0110
594 LARGE INTESTINE POLYP 76 0.0110
595 BLOOD BILIRUBIN INCREASED 296 0.0109
596 DRUG EFFECTIVE FOR UNAPPROVED INDICATION 318 0.0108
597 LOWER GASTROINTESTINAL HAEMORRHAGE 80 0.0108
598 SKIN ULCER 279 0.0108
599 LYMPHOMA 165 0.0107
600 APHTHOUS ULCER 81 0.0104
601 DERMATITIS 218 0.0104
602 AGRANULOCYTOSIS 193 0.0104
603 HEPATIC CIRRHOSIS 194 0.0103
604 MITRAL VALVE INCOMPETENCE 116 0.0102
605 VASCULITIS 119 0.0102
606 FACIAL PARALYSIS 87 0.0102
607 RENAL CYST 81 0.0102
608 ABORTION INDUCED 96 0.0102
609 MYOCARDITIS 116 0.0101
610 FLUID OVERLOAD 147 0.0101
611 ATAXIA 117 0.0098
612 C-REACTIVE PROTEIN INCREASED 358 0.0098
613 RENAL FAILURE ACUTE 417 0.0098
614 ULCER 156 0.0098
615 CEREBRAL HAEMORRHAGE 348 0.0097
616 MYELOSUPPRESSION 350 0.0097
617 MASS 135 0.0096
618 CELLULITIS 486 0.0096
619 UVEITIS 130 0.0096
620 LIVE BIRTH 80 0.0096
621 PULMONARY HYPERTENSION 199 0.0095
622 SKIN HYPERPIGMENTATION 82 0.0095
623 INTRAOCULAR PRESSURE INCREASED 121 0.0095
624 DRUG-INDUCED LIVER INJURY 297 0.0095
625 HYPONATRAEMIA 532 0.0094
626 SKIN CANCER 201 0.0093
627 METASTASES TO LIVER 164 0.0093
628 IMMUNODEFICIENCY 139 0.0093
629 HAEMOPTYSIS 260 0.0093
630 MYOCLONUS 111 0.0093
631 HAEMATOMA 241 0.0093
632 CONJUNCTIVITIS 172 0.0093
633 MYOCARDIAL ISCHAEMIA 105 0.0092
634 DISEASE PROGRESSION 1088 0.0092
635 CONDITION AGGRAVATED 2781 0.0091
636 PULMONARY OEDEMA 409 0.0091
637 KIDNEY INFECTION 179 0.0091
638 CARDIOMYOPATHY 134 0.0091
639 IMMUNE SYSTEM DISORDER 119 0.0090
640 HEPATITIS 231 0.0090
641 APPENDICITIS 84 0.0090
642 COLITIS ULCERATIVE 401 0.0090
643 UPPER RESPIRATORY TRACT INFECTION 413 0.0089
644 EOSINOPHILIA 155 0.0088
645 HYPERTENSION 1857 0.0088
646 PRODUCT PRESCRIBING ISSUE 190 0.0087
647 HAEMOGLOBIN DECREASED 887 0.0086
648 ALTERED STATE OF CONSCIOUSNESS 186 0.0086
649 CARDIAC ARREST 708 0.0086
650 SUPRAVENTRICULAR TACHYCARDIA 82 0.0086
651 MELAENA 188 0.0085
652 PNEUMONIA ASPIRATION 213 0.0085
653 GASTROINTESTINAL DISORDER 763 0.0085
654 BLOOD ALKALINE PHOSPHATASE INCREASED 210 0.0084
655 RENAL INJURY 249 0.0084
656 CYTOKINE RELEASE SYNDROME 168 0.0084
657 CARDIOMEGALY 103 0.0084
658 HAEMATOCRIT DECREASED 165 0.0083
659 DRUG INTOLERANCE 801 0.0083
660 ALANINE AMINOTRANSFERASE INCREASED 501 0.0082
661 HYPOCALCAEMIA 154 0.0081
662 OSTEONECROSIS 264 0.0080
663 HEPATIC STEATOSIS 149 0.0080
664 LACTIC ACIDOSIS 257 0.0079
665 METASTASES TO BONE 130 0.0079
666 TREATMENT NONCOMPLIANCE 433 0.0079
667 CIRCULATORY COLLAPSE 134 0.0079
668 GASTRITIS 207 0.0079
669 JAUNDICE 211 0.0078
670 LIVER FUNCTION TEST INCREASED 168 0.0078
671 SCRATCH 82 0.0078
672 RASH MACULO-PAPULAR 172 0.0077
673 GASTROINTESTINAL HAEMORRHAGE 643 0.0077
674 ELECTROCARDIOGRAM QT PROLONGED 276 0.0077
675 HYPOPHAGIA 196 0.0077
676 NODULE 99 0.0076
677 INTENTIONAL PRODUCT USE ISSUE 664 0.0076
678 INFLAMMATION 391 0.0076
679 DYSURIA 278 0.0075
680 LIVER DISORDER 333 0.0075
681 TENDERNESS 78 0.0075
682 THERAPEUTIC RESPONSE DECREASED 448 0.0074
683 DELIRIUM 256 0.0074
684 ABORTION SPONTANEOUS 295 0.0074
685 UPPER GASTROINTESTINAL HAEMORRHAGE 123 0.0073
686 ASPIRATION 80 0.0073
687 ASPARTATE AMINOTRANSFERASE INCREASED 388 0.0073
688 RESPIRATORY DISORDER 216 0.0072
689 GAMMA-GLUTAMYLTRANSFERASE INCREASED 160 0.0072
690 APHASIA 218 0.0072
691 TREMOR 1198 0.0072
692 VENTRICULAR FIBRILLATION 80 0.0072
693 OBSTRUCTIVE AIRWAYS DISORDER 80 0.0072
694 CHOLECYSTITIS 85 0.0071
695 DIARRHOEA 4599 0.0071
696 SKIN EXFOLIATION 601 0.0071
697 OEDEMA 386 0.0071
698 FISTULA 80 0.0071
699 IMPAIRED HEALING 233 0.0071
700 ISCHAEMIC STROKE 125 0.0070
701 STOMATITIS 423 0.0070
702 NERVOUS SYSTEM DISORDER 217 0.0069
703 VENTRICULAR TACHYCARDIA 114 0.0069
704 HEPATIC CYTOLYSIS 88 0.0069
705 DRUG INEFFECTIVE 9055 0.0069
706 SCAB 78 0.0068
707 ANOREXIA 88 0.0068
708 LIVER INJURY 167 0.0068
709 DIPLOPIA 175 0.0067
710 PULMONARY FIBROSIS 128 0.0067
711 PARALYSIS 95 0.0066
712 CARDIAC FAILURE 528 0.0066
713 ABDOMINAL PAIN 1530 0.0066
714 DIVERTICULITIS 181 0.0065
715 HEPATIC ENZYME INCREASED 437 0.0064
716 OSTEOPENIA 97 0.0064
717 PHARYNGITIS 79 0.0064
718 POST PROCEDURAL COMPLICATION 122 0.0063
719 PSYCHOTIC DISORDER 187 0.0063
720 RED BLOOD CELL COUNT DECREASED 181 0.0063
721 MUSCLE ATROPHY 80 0.0063
722 CYSTITIS 201 0.0063
723 DEEP VEIN THROMBOSIS 410 0.0063
724 COMA 300 0.0063
725 SINUS TACHYCARDIA 89 0.0063
726 HAEMORRHOIDS 120 0.0061
727 DEHYDRATION 815 0.0061
728 ACUTE MYOCARDIAL INFARCTION 180 0.0061
729 PANCREATITIS 322 0.0061
730 BLOOD TRIGLYCERIDES INCREASED 107 0.0060
731 PRODUCTIVE COUGH 289 0.0060
732 DEPRESSED LEVEL OF CONSCIOUSNESS 239 0.0060
733 DRY EYE 300 0.0060
734 PLATELET COUNT DECREASED 639 0.0060
735 PULMONARY CONGESTION 79 0.0060
736 SARS-COV-2 TEST POSITIVE 79 0.0060
737 HALLUCINATION, VISUAL 126 0.0060
738 TACHYCARDIA 530 0.0060
739 LUNG DISORDER 292 0.0060
740 BLOOD PRESSURE SYSTOLIC INCREASED 115 0.0059
741 PRODUCT USE ISSUE 1105 0.0059
742 DRUG TOXICITY 80 0.0059
743 OSTEOPOROSIS 239 0.0058
744 IMPAIRED GASTRIC EMPTYING 79 0.0058
745 THERAPEUTIC PRODUCT EFFECT INCOMPLETE 412 0.0058
746 DRY SKIN 769 0.0058
747 RASH ERYTHEMATOUS 275 0.0057
748 HYPOKALAEMIA 265 0.0057
749 GOUT 103 0.0057
750 WHITE BLOOD CELL COUNT INCREASED 220 0.0057
751 HEPATOCELLULAR INJURY 81 0.0057
752 SYSTEMIC LUPUS ERYTHEMATOSUS 200 0.0056
753 HYPOTENSION 1121 0.0056
754 DISCOMFORT 338 0.0055
755 PERICARDITIS 93 0.0055
756 DYSARTHRIA 208 0.0055
757 SUBDURAL HAEMATOMA 79 0.0055
758 DYSPNOEA EXERTIONAL 206 0.0055
759 SEIZURE 628 0.0054
760 INFLUENZA 601 0.0054
761 HAEMATOCHEZIA 294 0.0053
762 INTESTINAL OBSTRUCTION 199 0.0053
763 ATRIAL FIBRILLATION 511 0.0052
764 EPILEPSY 160 0.0052
765 PLASMA CELL MYELOMA 204 0.0052
766 PULMONARY EMBOLISM 496 0.0052
767 VISUAL ACUITY REDUCED 173 0.0052
768 INCORRECT ROUTE OF PRODUCT ADMINISTRATION 89 0.0052
769 HYPOTHYROIDISM 165 0.0052
770 ABDOMINAL PAIN LOWER 130 0.0051
771 THERAPEUTIC RESPONSE SHORTENED 170 0.0051
772 NEOPLASM MALIGNANT 342 0.0051
773 BLINDNESS 208 0.0051
774 OEDEMA PERIPHERAL 622 0.0051
775 BODY TEMPERATURE INCREASED 104 0.0051
776 BLOOD SODIUM DECREASED 96 0.0051
777 GENERAL PHYSICAL HEALTH DETERIORATION 588 0.0051
778 LOCALISED INFECTION 122 0.0050
779 LOWER RESPIRATORY TRACT INFECTION 226 0.0050
780 RHABDOMYOLYSIS 205 0.0049
781 PRODUCT PRESCRIBING ERROR 117 0.0049
782 WEIGHT DECREASED 1359 0.0049
783 THROMBOSIS 388 0.0048
784 UNRESPONSIVE TO STIMULI 124 0.0048
785 URINARY RETENTION 160 0.0048
786 EYE PRURITUS 161 0.0048
787 SKIN DISORDER 159 0.0048
788 PRURITUS 1827 0.0047
789 VOMITING 2235 0.0047
790 CARDIO-RESPIRATORY ARREST 197 0.0047
791 BLOOD PRESSURE FLUCTUATION 113 0.0047
792 LOSS OF PERSONAL INDEPENDENCE IN DAILY ACTIVITIES 226 0.0047
793 HOSPITALISATION 717 0.0047
794 CHILLS 537 0.0046
795 DRUG ERUPTION 81 0.0046
796 ANAPHYLACTIC REACTION 251 0.0045
797 GASTROENTERITIS VIRAL 82 0.0045
798 HAEMORRHAGE 468 0.0045
799 PHOTOPHOBIA 84 0.0045
800 COUGH 1244 0.0044
801 SEROTONIN SYNDROME 85 0.0044
802 RASH 1922 0.0044
803 RASH MACULAR 154 0.0044
804 RESTLESS LEGS SYNDROME 78 0.0043
805 FLUID RETENTION 218 0.0043
806 EYE PAIN 240 0.0042
807 DECREASED APPETITE 987 0.0042
808 DISORIENTATION 168 0.0042
809 LABORATORY TEST ABNORMAL 125 0.0042
810 ERYTHEMA 869 0.0042
811 OXYGEN SATURATION DECREASED 236 0.0042
812 NEUROPATHY PERIPHERAL 399 0.0042
813 CONFUSIONAL STATE 672 0.0042
814 DYSPHAGIA 392 0.0041
815 SLEEP DISORDER 290 0.0041
816 HAEMATEMESIS 104 0.0041
817 APPLICATION SITE PAIN 90 0.0041
818 GLYCOSYLATED HAEMOGLOBIN INCREASED 103 0.0041
819 OCULAR HYPERAEMIA 193 0.0041
820 WHITE BLOOD CELL COUNT DECREASED 440 0.0041
821 CATARACT 241 0.0040
822 BRADYCARDIA 214 0.0040
823 DEATH 3467 0.0040
824 NIGHT SWEATS 126 0.0039
825 NEPHROLITHIASIS 179 0.0039
826 PRODUCT DOSE OMISSION IN ERROR 109 0.0038
827 NEUTROPHIL COUNT DECREASED 155 0.0038
828 MUSCULAR WEAKNESS 432 0.0038
829 CARDIOVASCULAR DISORDER 96 0.0038
830 PRODUCT AVAILABILITY ISSUE 86 0.0038
831 SINUSITIS 387 0.0038
832 CORONARY ARTERY DISEASE 114 0.0038
833 RASH PRURITIC 203 0.0037
834 EYE IRRITATION 215 0.0037
835 EYE DISORDER 121 0.0037
836 RASH PAPULAR 82 0.0037
837 ACNE 277 0.0036
838 HYPOGLYCAEMIA 175 0.0036
839 LETHARGY 207 0.0036
840 SWELLING 335 0.0036
841 BRONCHITIS 262 0.0035
842 DYSPNOEA 1992 0.0035
843 SKIN DISCOLOURATION 160 0.0035
844 TYPE 2 DIABETES MELLITUS 117 0.0035
845 ABDOMINAL DISTENSION 360 0.0034
846 CHOLELITHIASIS 111 0.0034
847 ANGINA PECTORIS 95 0.0033
848 COGNITIVE DISORDER 154 0.0033
849 INTERNATIONAL NORMALISED RATIO INCREASED 94 0.0033
850 ASTHENIA 1236 0.0033
851 LUNG NEOPLASM MALIGNANT 135 0.0033
852 EXPOSURE VIA SKIN CONTACT 85 0.0033
853 GASTROOESOPHAGEAL REFLUX DISEASE 263 0.0033
854 SWELLING FACE 212 0.0033
855 PSORIASIS 425 0.0033
856 CONVULSION 185 0.0032
857 ANGIOEDEMA 142 0.0032
858 NAUSEA 2529 0.0032
859 HEADACHE 1988 0.0032
860 BLISTER 177 0.0031
861 MENTAL DISORDER 136 0.0031
862 THERAPY INTERRUPTED 223 0.0031
863 EAR INFECTION 83 0.0031
864 BLOOD PRESSURE INCREASED 476 0.0031
865 ALOPECIA 607 0.0031
866 SURGERY 181 0.0031
867 ARRHYTHMIA 145 0.0031
868 VERTIGO 184 0.0030
869 PALLOR 82 0.0030
870 PAIN OF SKIN 81 0.0030
871 ABDOMINAL PAIN UPPER 615 0.0030
872 BLOOD CHOLESTEROL INCREASED 135 0.0029
873 MYALGIA 491 0.0029
874 INFUSION RELATED REACTION 191 0.0029
875 ABDOMINAL DISCOMFORT 483 0.0029
876 CHEST PAIN 531 0.0029
877 WEIGHT INCREASED 641 0.0029
878 VISUAL IMPAIRMENT 353 0.0028
879 ACCIDENTAL OVERDOSE 104 0.0028
880 RESPIRATORY ARREST 78 0.0028
881 URINARY INCONTINENCE 82 0.0028
882 THERAPY CESSATION 141 0.0027
883 BLOOD POTASSIUM DECREASED 81 0.0027
884 BURNING SENSATION 188 0.0027
885 BLOOD PRESSURE DECREASED 178 0.0027
886 BLOOD CREATINE PHOSPHOKINASE INCREASED 77 0.0027
887 OROPHARYNGEAL PAIN 246 0.0027
888 THERAPEUTIC PRODUCT EFFECT DECREASED 119 0.0027
889 VISION BLURRED 364 0.0026
890 CONTRAINDICATED PRODUCT ADMINISTERED 80 0.0026
891 AGITATION 192 0.0026
892 PERIPHERAL SWELLING 401 0.0026
893 SKIN IRRITATION 119 0.0026
894 INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION 461 0.0026
895 DYSPEPSIA 249 0.0025
896 FATIGUE 1968 0.0025
897 RHINORRHOEA 162 0.0025
898 NEOPLASM PROGRESSION 86 0.0025
899 RECTAL HAEMORRHAGE 106 0.0025
900 MALAISE 1078 0.0025
901 RHEUMATOID ARTHRITIS 279 0.0025
902 EPISTAXIS 183 0.0024
903 CARDIAC FAILURE CONGESTIVE 196 0.0024
904 ADVERSE DRUG REACTION 219 0.0024
905 PRODUCT DOSE OMISSION ISSUE 704 0.0024
906 HEART RATE INCREASED 237 0.0024
907 AMNESIA 155 0.0024
908 EYE SWELLING 88 0.0024
909 RESTLESSNESS 86 0.0023
910 CONTUSION 224 0.0023
911 LOSS OF CONSCIOUSNESS 297 0.0023
912 ARTHRALGIA 960 0.0023
913 OVERDOSE 497 0.0023
914 DEPRESSED MOOD 121 0.0023
915 BLOOD GLUCOSE INCREASED 427 0.0023
916 GAIT DISTURBANCE 433 0.0023
917 POLLAKIURIA 93 0.0022
918 CEREBROVASCULAR ACCIDENT 375 0.0022
919 ILLNESS 227 0.0022
920 NASAL CONGESTION 128 0.0022
921 URTICARIA 355 0.0021
922 BACK PAIN 491 0.0021
923 PSORIATIC ARTHROPATHY 85 0.0021
924 CHEST DISCOMFORT 212 0.0021
925 SPEECH DISORDER 108 0.0021
926 SKIN BURNING SENSATION 147 0.0020
927 PRODUCT SUBSTITUTION ISSUE 118 0.0020
928 CONSTIPATION 446 0.0020
929 ASTHMA 231 0.0020
930 INSOMNIA 543 0.0020
931 PAIN 1245 0.0020
932 NASOPHARYNGITIS 368 0.0020
933 SYNCOPE 198 0.0020
934 ILL-DEFINED DISORDER 120 0.0020
935 THERAPEUTIC RESPONSE UNEXPECTED 88 0.0020
936 ARTHRITIS 154 0.0020
937 MEDICATION ERROR 107 0.0019
938 PAIN IN EXTREMITY 567 0.0019
939 FALL 633 0.0019
940 MUSCULOSKELETAL PAIN 99 0.0019
941 CARDIAC DISORDER 174 0.0019
942 AGGRESSION 93 0.0019
943 HALLUCINATION 140 0.0019
944 DISTURBANCE IN ATTENTION 100 0.0019
945 SOMNOLENCE 369 0.0018
946 BONE PAIN 106 0.0018
947 INCORRECT DOSE ADMINISTERED 403 0.0018
948 DRY MOUTH 142 0.0017
949 DEPRESSION 397 0.0017
950 UNEVALUABLE EVENT 131 0.0017
951 HYPERSENSITIVITY 320 0.0017
952 MUSCULOSKELETAL STIFFNESS 151 0.0017
953 INJECTION SITE SWELLING 131 0.0017
954 PALPITATIONS 198 0.0017
955 MALIGNANT NEOPLASM PROGRESSION 173 0.0017
956 PARAESTHESIA 260 0.0017
957 MEMORY IMPAIRMENT 227 0.0017
958 MYOCARDIAL INFARCTION 286 0.0016
959 MIGRAINE 156 0.0016
960 DIZZINESS 814 0.0016
961 INFLUENZA LIKE ILLNESS 134 0.0016
962 IRRITABILITY 97 0.0016
963 HYPOAESTHESIA 241 0.0016
964 INTENTIONAL PRODUCT MISUSE 140 0.0016
965 NECK PAIN 89 0.0016
966 WHEEZING 94 0.0016
967 FLATULENCE 89 0.0016
968 BALANCE DISORDER 135 0.0016
969 DYSPHONIA 91 0.0016
970 MUSCLE SPASMS 285 0.0016
971 FEELING HOT 94 0.0015
972 ANXIETY 429 0.0015
973 INJECTION SITE PAIN 456 0.0015
974 PRODUCT DOSE OMISSION 93 0.0014
975 NO ADVERSE EVENT 256 0.0014
976 MOBILITY DECREASED 98 0.0014
977 JOINT SWELLING 164 0.0014
978 HYPERHIDROSIS 175 0.0014
979 DYSGEUSIA 97 0.0013
980 ACCIDENTAL EXPOSURE TO PRODUCT 131 0.0013
981 INJECTION SITE PRURITUS 85 0.0013
982 PROSTATE CANCER 98 0.0012
983 FLUSHING 117 0.0011
984 INJECTION SITE REACTION 78 0.0011
985 ADVERSE EVENT 102 0.0011
986 FEELING ABNORMAL 263 0.0011
987 SUICIDAL IDEATION 98 0.0011
988 INJECTION SITE ERYTHEMA 118 0.0010
989 EMOTIONAL DISTRESS 102 0.0008
990 WRONG TECHNIQUE IN PRODUCT USAGE PROCESS 142 0.0007
991 PRODUCT QUALITY ISSUE 93 0.0007
992 DRUG DOSE OMISSION 98 0.0006